Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Mario I Vega, PhD, Yijiang Shi, MD PhD, Patrick Frost, PhD, Sara Huerta-Yepez, PhD, Alan Lichtenstein, MD

Blood (2019) 134 (Supplement_1): 1821.

https://doi.org/10.1182/blood-2019-121480

Published: 2019

Journal Articles

Targeting of the Hypoxia-Induced Acid Microenvironment of Multiple Myeloma Cells Increases Hypoxia-Mediated Apoptosis

Gilberto Gastelum, MS, Jeffery Kraut, MD, Aleksandra Poteshkina, BS, Edgar Artiga, MS, Geraldine Weckstein, Patrick Frost, PhD

Blood (2017) 130 (Supplement 1): 4376.

https://doi.org/10.1182/blood.V130.Suppl_1.4376.4376

Published: 2017

Journal Articles

Deptor As a Target with Chemical Inhibitors; Alternative Therapy in Multiple Myeloma

Mario Vega, PhD, Patrick Frost, PhD, Carolyne Bardeleben, PhD, Yijiang Shi, MD PhD, Sara Huerta-Yepez, PhD, Alan Lichtenstein, MD

Blood (2017) 130 (Supplement 1): 3833.

https://doi.org/10.1182/blood.V130.Suppl_1.3833.3833

Published: 2017

Journal Articles

The Internal Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in Vivo

Patrick Frost, Joseph Gera, Alan K. Lichtenstein, M.D.

Blood (2012) 120 (21): 1659.

https://doi.org/10.1182/blood.V120.21.1659.1659

Published: 2012

Journal Articles

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Bao Hoang, Patrick Frost, Yijiang Shi, Eileen Belanger, Angelica Benavides, Gholam Pezeshkpour, Susanna Cappia, Tommasina Guglielmelli, Joseph Gera, Alan Lichtenstein

Blood (2010) 116 (22): 4560–4568.

https://doi.org/10.1182/blood-2010-05-285726

Published: 2010

Includes: Supplemental data

Journal Articles

AKT Kinase Addiction in Multiple Myeloma.

Carolyne Bardeleben, PhD, Huajun Yan, PhD, Patrick Frost, PhD, Bao Hoang, PhD, Yijiang Shi, MD, PhD, Sanjai Sharma, MD, Alan Lichtenstein, MD

Blood (2006) 108 (11): 3431.

https://doi.org/10.1182/blood.V108.11.3431.3431

Published: 2006

Journal Articles

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance

Bao Hoang, Li Zhu, Yijiang Shi, Patrick Frost, Huajun Yan, Sanjai Sharma, Sherven Sharma, Lee Goodglick, Steven Dubinett, Alan Lichtenstein

Blood (2006) 107 (11): 4484–4490.

https://doi.org/10.1182/blood-2005-09-3926

Published: 2006

Journal Articles

Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.

Patrick Frost, PhD, Bao Hoang, PhD, Yijiang Shi, MD, Huajun Yan, PhD, Alan Lichtenstein, MD

Blood (2005) 106 (11): 3406.

https://doi.org/10.1182/blood.V106.11.3406.3406

Published: 2005

Journal Articles

Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.

Huajun Yan, PhD, Patrick Frost, PhD, Yijiang Shi, MD & PhD, Bao Hoang, PhD, Sanjai Sharma, MD, Myrna Fisher, Joseph Gera, PhD, Alan Lichtenstein, MD

Blood (2005) 106 (11): 1582.

https://doi.org/10.1182/blood.V106.11.1582.1582

Published: 2005

Journal Articles

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

Patrick Frost, Farhad Moatamed, Bao Hoang, Yijiang Shi, Joseph Gera, Huajun Yan, Philip Frost, Jay Gibbons, Alan Lichtenstein

Blood (2004) 104 (13): 4181–4187.

https://doi.org/10.1182/blood-2004-03-1153

Published: 2004

Journal Articles

AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.

Patrick Frost, Ph.D., Bao Hoang, Ph.D., Joseph Gera, Ph.D., Anushree Sharma, Yijiang Shi, Ph.D., Huajun Yan, Ph.D., Alan Lichtenstein, MD.

Blood (2004) 104 (11): 646.

https://doi.org/10.1182/blood.V104.11.646.646

Published: 2004

Journal Articles

MTOR Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Upregulating the IGF-1/IRS-1/PI-3 Kinase Cascade.

Yijiang Shi, Ph D, HuaJun Yan, Ph D, Patrick Frost, Ph D, Bao Hoang, Ph D, Joseph Gera, Ph D, Alan Lichtenstein, MD

Blood (2004) 104 (11): 3350.

https://doi.org/10.1182/blood.V104.11.3350.3350

Published: 2004

NARROW

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Targeting of the Hypoxia-Induced Acid Microenvironment of Multiple Myeloma Cells Increases Hypoxia-Mediated Apoptosis

Deptor As a Target with Chemical Inhibitors; Alternative Therapy in Multiple Myeloma

The Internal Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in Vivo

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

AKT Kinase Addiction in Multiple Myeloma.

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance

Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.

Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.

MTOR Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Upregulating the IGF-1/IRS-1/PI-3 Kinase Cascade.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only